Yasheng announced the use of herbal medicine into the field of against COVID-19 projects

 

 

Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the prevention of pericarditis and familial Mediterranean fever.Colchicine is taken by mouth.
 
July 29, 2009, colchicine won FDA approval in the United States as a stand-alone drug for the treatment of acute flares of gout and familial Mediterranean fever.It had previously been approved as an ingredient in an FDA-approved combination product for gout.
 
As the race to combat the coronavirus continues, researchers believe they have found new use for an old drug, one that has been primarily used to treat gout a form of arthritis.
 
A study conducted by a team of researchers with the Montreal Heart Institute found that colchicine could be the first oral medication to treat non-hospitalized patients with COVID-19.
A team of researchers with the Montreal Heart Institute believe they've found an effective drug to help fight COVID-19. In a clinical study, they found Colchicine a drug that's been around for over a century  can reduce symptoms of the coronavirus and the risk of death.
 This major scientific discovery makes colchicine the world's first oral drug that could be used to treat non-hospitalized patients with COVID-19.
 
Our research shows the efficacy of colchicine treatment in preventing the cytokine storm phenomenon and reducing the complications associated with COVID-19, said Dr. Jean-Claude Tardif, Director of the MHI Research Center, Professor of Medicine at the Universit de Montral and Principal Investigator of the COLCORONA trial. We are pleased to offer the first oral medication in the world whose use could have a significant impact on public health and potentially prevent COVID-19 complications for millions of patients.
 
Furthermore, the analysis of the 4,159 Covid-19 patients receiving colchicine showed statistically significant reductions in the risk of death or hospitalisation versus placebo.
 
In these Covid-19 patients, the drug lowered hospitalisations by 25%, the requirement for mechanical ventilation by 50% and deaths by 44%.
The Institute noted that the latest scientific discovery makes colchicine the world's first oral drug which can be used for treating non-hospitalised Covid-19 patients.